➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Harvard Business School
Mallinckrodt
Colorcon
Merck

Last Updated: August 5, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for F901318


Email this page to a colleague

« Back to Dashboard

What is the drug development status for F901318?

F901318 is an investigational drug.

There have been 18 clinical trials for F901318. The most recent clinical trial was a Phase 1 trial, which was initiated on June 6th 2018.

The most common disease conditions in clinical trials are Aspergillosis, Leukemia, Myeloid, Acute, and Mycoses. The leading clinical trial sponsors are F2G Ltd., Quotient Clinical, and Hammersmith Medicines Research.

There are two US patents protecting this investigational drug and twenty-five international patents.

Recent Clinical Trials for F901318
TitleSponsorPhase
A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic ImpairmentF2G Ltd.Phase 1
A Biopharmaceutics Study to Assess the Pharmacokinetics of Single Oral and IV Doses of OlorofimCovancePhase 1
A Biopharmaceutics Study to Assess the Pharmacokinetics of Single Oral and IV Doses of OlorofimF2G Ltd.Phase 1

See all F901318 clinical trials

Clinical Trial Summary for F901318

Top disease conditions for F901318
Top clinical trial sponsors for F901318

See all F901318 clinical trials

International Patents for F901318

Drugname Country Document Number Estimated Expiration Related US Patent
F901318 Australia AU2015348043 2034-11-21 ⤷  Try it Free
F901318 Brazil BR112017010439 2034-11-21 ⤷  Try it Free
F901318 Canada CA2982660 2034-11-21 ⤷  Try it Free
F901318 China CN107207470 2034-11-21 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
McKinsey
Mallinckrodt
McKesson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.